Pfizer taps WuXi for new contract studies
This article was originally published in Scrip
WuXi PharmaTech has struck a new three-year contract with Pfizerto conduct in vitro absorption, distribution, metabolism and excretion (ADME) studies. The firms will develop ADME assays to screen and optimise new drug compounds synthesised for Pfizer by WuXi. The Chinese contract research firm already conducts a variety of work for Pfizer, including in the synthetic and medicinal chemistry areas.